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Schwann cells are the main source of paracrine support to motor neurons. Oxidative
stress and mitochondrial dysfunction have been correlated to motor neuron death in
Amyotrophic Lateral Sclerosis (ALS). Despite the involvement of Schwann cells in early
neuromuscular disruption in ALS, detailed molecular events of a dying-back triggering
are unknown. Sciatic nerves of presymptomatic (60-day-old) SOD1G93A mice were
submitted to a high-density oligonucleotide microarray analysis. DAVID demonstrated
the deregulated genes related to death, stress and mitochondrion, which allowed the
identification of Cell cycle, ErbB signaling, Tryptophan metabolism and Rig-I-like receptor
signaling as the most representative KEGG pathways. The protein-protein interaction
networks based upon deregulated genes have identified the top hubs (TRAF2, H2AFX,
E2F1, FOXO3, MSH2, NGFR, TGFBR1) and bottlenecks (TRAF2, E2F1, CDKN1B,
TWIST1, FOXO3). Schwann cells were enriched from the sciatic nerve of presymptomatic
mice using flow cytometry cell sorting. qPCR showed the up regulated (Ngfr, Cdnkn1b,
E2f1, Traf2 and Erbb3, H2afx, Cdkn1a, Hspa1, Prdx, Mapk10) and down-regulated
(Foxo3, Mtor) genes in the enriched Schwann cells. In conclusion, molecular analyses
in the presymptomatic sciatic nerve demonstrated the involvement of death, oxidative
stress, and mitochondrial pathways in the Schwann cell non-autonomous mechanisms
in the early stages of ALS.
Keywords: ALS, SOD1G93A, pre-symptomatic, sciatic nerve, microarray, flow cytometry sorting, Schwann cells,
network analysis
Introduction
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by a
selective death of motor neurons of the spinal cord, brainstem and cerebral cortex, leading to
progressive paralysis. The patient’s death is often due to a respiratory failure, usually within 3–5
years from diagnosis (Kiernan et al., 2011).
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ALS pathogenesis is poorly understood and the proposed
mechanisms related to neurodegeneration seem to be
multifactorial and include mitochondrial dysfunction, oxidative
stress, protein aggregation and axonal transport impairment
(Boillée et al., 2006a; de Vos et al., 2007). Additionally,
mechanisms associated with motor neuron degeneration involve
non-neuronal cells (Boillée et al., 2006a,b; Yamanaka et al., 2008;
Wang et al., 2011), as seen by toxicity in neuron-glial co-culture
experiments and also by the activation of molecular pathways
related to paracrine stress signaling (Boillée et al., 2006a,b;
Ferraiuolo et al., 2007; Kiernan et al., 2011).
Evidence obtained from studies on early axon and
neuromuscular junction events in ALS patients and a mouse
model have indicated the presence of peripheral motor neuron
dysfunction before the activation of death pathways and the
onset of clinical symptoms (Fischer et al., 2004; Gould et al.,
2006; Moloney et al., 2014). Indeed, the peripheral events
seem to proceed toward soma in a retrograde dying-back
manner (Coleman and Perry, 2002; Fischer et al., 2004; Saxena
and Caroni, 2007; Rocha et al., 2013). Oxidative stress and
compromised mitochondria represent one set of proposed
mechanisms underlying peripheral ALS dysfunction (Barber
et al., 2006; Cozzolino and Carrì, 2012; Cozzolino et al.,
2013).
The Schwann cell is the major functional cell type supporting
axonal integrity (Mirsky and Jessen, 1999). Recent evidence
suggests that Schwann cells may contribute to ALS distal
axonopathy (Fischer et al., 2004; deWinter et al., 2006; Gorlewicz
et al., 2009; Keller et al., 2009; Lobsiger et al., 2009; Chen et al.,
2010; Verheijen et al., 2014). For instance, the up-regulation
of inducible nitric oxide synthase and semaphorin 3A in the
Schwann cells close to terminal ﬁbers of the sciatic nerve has
been associated with dying-back mechanisms in presymptomatic
ALS mice (de Winter et al., 2006; Keller et al., 2009; Chen
et al., 2010; Malaspina et al., 2010; Venkova et al., 2014).
Furthermore, accumulation of axonal ribosomes in Schwann
cells bearing mutant hSOD1 in a presymptomatic phase of ALS
mouse model further suggests an early involvment of this glial
cell type in the pathogenesis of the disease (Verheijen et al.,
2014).
Microarray analyses have been useful in identifying new
molecular cues potentially involved in ALS pathogenesis both
in postmortem human tissue and also in several clinical stages
of experimental animal models of ALS (Olsen et al., 2001;
Hensley et al., 2002; Yoshihara et al., 2002; Dangond et al., 2004;
Perrin et al., 2005; Ferraiuolo et al., 2007, 2009; Fukada et al.,
2007; Vargas et al., 2008; Kudo et al., 2010; Boutahar et al.,
2011; Cooper-Knock et al., 2012; de Oliveira et al., 2013, 2014;
Maximino et al., 2014). However, there is a lack of information
on gene expression in peripheral motor nerves in ALS despite
the importance of recently described dying-back events in this
disorder. Furthermore, an evaluation of dysregulated genes in
speciﬁc, enriched cell populations obtained by cell sorting might
extend these molecular analyses at cellular level.
By means of a high-density oligonucleotide microarray
analysis linked to speciﬁc tools capable of identifying distinct
cellular components and biological processes, the aim of this
work was to determine whether the expression of genes involved
in the regulation of death, stress and mitochondrial function
was dysregulated in the sciatic nerve of the SOD1G93A mouse
model during the presymptomatic stage of ALS. This work has
also evaluated the modulation of selected molecules in enriched
sciatic nerve-derived Schwann cells, thus detailing the role of
these glial cells in the early phase of this disease.
Materials and Methods
Animal and Tissue Sample
Transgenic SOD1G93A mice (The Jackson Laboratory, Bar
Harbor, ME, USA) were crossbred and the colony was
maintained in a speciﬁc pathogen-free environment within the
animal facility of the University of São Paulo Medical School
(São Paulo, Brazil) as described previously (Gurney, 1994;
Scorisa et al., 2010; Alves et al., 2011). Animals were kept
under controlled temperature and humidity conditions with a
standardized light–dark cycle (lights on at 7:00 a.m. and oﬀ at
7:00 p.m.) and free access to food pellets and tap water. Mice
were genotyped by PCR ampliﬁcation of tail extracted DNA
which identiﬁed the presence of the human SOD1 mutated gene
(mSOD1) (Gurney, 1994; Scorisa et al., 2010; Alves et al., 2011).
The Transgenic SOD1G93A mice express high number of mutant
human SOD1 copies (Gurney, 1994; Verheijen et al., 2014). The
study was conducted under protocols approved by the Ethical
Animal Care and Use Committee at the University of São Paulo
and in accordance with the Guide for the Care and Use of
Laboratory Animals adopted by the National Institutes of Health.
Sixty-day-old presymptomatic male SOD1G93A mice and their
age-paired wild-type controls (∼20–25 g body weight) were used
in the experiments. No motor neuron death was seen in any
animal at this age (Alves et al., 2011), therefore the animals were
chosen for the present presymptomatic analyses. Animals were
killed by decapitation and sciatic nerves were removed, frozen
and stored at −80◦C for further use. Four mice were used in
each group for the microarray experiments. The quantitative
polymerase chain reaction (qPCR) analyses of sciatic nerves were
performed using samples from six diﬀerent mice from each
transgene and wild-type groups.
Immunofluorescence Labelings and Histological
Sections of Sciatic Nerve
Four animals per genotype were used for immunoﬂuorescence
labelings, according to previous publications (Guzen et al.,
2009; Batista et al., 2014). Mice were anesthetized with sodium
pentobarbital and euthanized by a transcardiac perfusion with
7ml isotonic saline at room temperature followed by 35ml
ﬁxation ﬂuid (4◦C) over a period of 6min. The ﬁxative consisted
of 4% paraformaldehyde (w/v) in 0.1M phosphate buﬀer (pH
6.9). The sciatic nerves were removed, kept in ﬁxative at 4◦C
for 90min and rinsed for 24 h in 10% sucrose dissolved in
PBS. Sciatic nerves were then frozen in dry ice-cooled (−40◦C)
isopentane (Sigma) and stored at a −80◦C freezer until use.
Longitudinal sections (5μm thick) were obtained using a cryostat
(Leica, CM3000, Germany). The sections were initially washed
for 2× 10min in PBS and then were incubated overnight in PBS
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containing 0.5% Triton X-100 (Sigma) and 1% bovine albumin
serum (BSA, Sigma) with a polyclonal rabbit antibody against
microtubule associated protein 2 (MAP2; diluted 1:200; Sigma),
growth associated protein 43 (GAP-43; diluted 1:200; Sigma),
S100 (diluted 1:200; Abcam) and p75NGF neurotrophin receptor
(p75; diluted 1:200; Abcam). After the incubation of the primary
antibodies, sections were washed for 2 × 10min in PBS and
incubated for 1 h in the dark at 37◦C with a dilution of Alexa
Fluor R© 488 or 594-conjugated secondary antibodies speciﬁc
for rabbit (1:200, all from Invitrogen, USA). Preparations were
mounted on microscope slides and counterstained with nuclear
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI; Vector,
USA). Digital images were obtained by means of an Olympus
BX-51 microscope (Olympus, USA).
In addition, four animals per genotype were processed to
histological staining using methylene blue. Brieﬂy, sciatic nerves
were ﬁxed in 2.5% glutaraldehyde, pH 7.4 (24 h). After extensive
wash, tissues were embedded in araldite and transverse semi-
thin sections (0.5μm thickness) were obtained. The sections were
stained with methylene blue and photomicrographed using an
Olympus BX-51 microscope (Olympus).
RNA Isolation and Microarray Experiments
The procedures for RNA isolation and microarray experiments
with sciatic nerve were described in our previous publication
(Maximino et al., 2014). Brieﬂy, RNAs from samples (25 ng)
and reference (100 ng) were reverse transcribed by the Low-
input RNA Linear Ampliﬁcation kit and then transcribed to Cy3-
labeled (samples) or Cy5-labeled (reference) RNAs according to
the manufacturer’s instructions (Agilent Technologies, USA) and
to our previously described protocols (de Oliveira et al., 2013).
Microarray Analysis
Raw image data were converted to numerical data using
the Agilent Feature Extraction Software, version 11.0.1.1, as
described in our previous study (Maximino et al., 2014; Alves
et al., 2015). Raw signal intensities were normalized using the
GeneSpring GX v12.6 software package (Agilent Technologies,
USA). After normalization, the probes were tested for diﬀerential
expression. GeneSpring GX was also used in the statistical
analyses of gene expressions between genotypes (SOD1G93A ×
wild-type), according to previous publications (Smyth, 2004; Fu
et al., 2014; Yang et al., 2014; Ryan et al., 2015; Wang et al., 2015).
Genes with p < 0.05 were considered diﬀerentially expressed.
The raw data from hybridizations are available on the Gene
Expression Omnibus Database, and the GEO accession number
is GSE69450.
Bioinformatic Analysis
The dysregulated genes were submitted for the following analyses
to provide information regarding their involvement with speciﬁc
cellular/molecular pathways related to ALS:
Functional Enrichment Analysis
The Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7b functional tool (https://david.ncifcrf.
gov/) (Huang Da et al., 2008) was used to identify genes
related to death, stress and mitochondrial function through
the Gene Ontology (GO) annotation database. The DAVID
analysis focused on the category: Biological Process and
Cellular Component. Stringency (EASE score set to 0.05)
parameters were selected to improve conﬁdence in the terms
designated as enriched. The Biological Process and Cellular
Component terms related to death, stress and mitochondrial
function were further organized using the BioVenn tool
(http://www.cmbi.ru.nl/cdd/biovenn/) (Hulsen et al., 2008)
which identiﬁes common and exclusively expressed genes
between lists.
In order to identify over-represented pathways, the GO terms
list containing genes related to death, stress and mitochondrion
was submitted to the DAVID tool using the Kyoto Encyclopedia
of Genes and Genomes (KEGG).
Protein Interaction Network Analysis
The Cytoscape plugin GeneMANIA (Warde-Farley et al.,
2010) was used to predict protein interactions from the
list of diﬀerentially expressed genes in the sciatic nerve
of presymptomatic SOD1G93A mice related to death, stress
and mitochondrion. The network was generated using only
information derived from the pathway and physical interactions
categories in GeneMANIA. The connectivity of the nodes
contained in the network was achieved by means of the node
centrality parameters “degree” and “betweenness,” using the
Cytoscape plug-in CentiScaPe (Scardoni et al., 2009). Node
degree is a local structure measure in networks that determines
the number of edges in each node. Conversely, betweenness
centrality is a global structure measure in networks that
determines the number of shortest paths passing through a
speciﬁc node while connecting, directly or indirectly, pairs of
nodes (Scardoni et al., 2009). A scatter plot was constructed
by inputting node degree and betweenness values for each
node in GraphPad Prism 5. The combination of such attributes
in the scatter plot allowed the visualization of hubs (nodes
with high node degree) and bottlenecks (nodes with high node
betweenness). Subnetworks were built using list of genes related
to death, stress and mitochondrion separately; scatter plots were
also constructed by inputting node degree and betweenness
values for each node in GraphPad Prism 5.
Flow Cytometry Sorting of Isolated Schwann
Cells and Fibroblast
Schwann cells and ﬁbroblasts were isolated by means of ﬂow
cytometry sorting from sciatic nerve explants of presymptomatic
SOD1G93A mice and their age-paired wild-type controls as
described in our previous publication (Maximino et al., 2014).
The sciatic nerve-derived cell suspension was submitted to a
double immunolabeling to identify Schwann cells and ﬁbroblasts
by means of a ﬂuorescein isothiocyanate (FITC)-conjugated
mouse p75NGF Receptor antibody (Abcam, USA) and a
ﬂuorescein phychoerythrin (PE-Cy5)-conjugated monoclonal
antibody against Thy-1 (Abcam, USA), respectively. The
p75NGF Receptor labeling was employed in the cell sorting
experiments because it is a well-characterized surface marker for
Schwann cells (Niapour et al., 2010). Cells were then analyzed
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for type and speciﬁcity as well as separated on a FACSAria III
Cell Sorter (BD Biosciences, USA). A maximum of 106 cells
were ressuspended in 500μl of buﬀer. Flow cytometry dot plot
Schwann cell and ﬁbroblast proﬁles are shown in Figures 1A–D.
Of note, the ﬂow cytometry sorting Schwann cells of ALS mice
did not showmorphological diﬀerences (cell size and cytoplasmic
granules) compared to control mice (Figures 1C,D). Also, the
Schwann cells of ALS mice expressed high levels of mutant
human SOD1, while no signal was seen in the Schwann cells of
wild-type mice, as evidenced by PCR (Figure 1E).
Total RNA from enriched Schwann cells was extracted using
Trizol (Life Technologies, USA) according to the manufacturer’s
protocol. The quantity (NanoDrop 1000 Spectrophotometer) and
quality (Agilent 2100 bioanalyzer, RNA 6000 Pico LabChip) of
RNAs were analyzed as described in our previous publication
(Maximino et al., 2014). Also, the Schwann cell samples were
submitted to PCR analyses in order to assess contamination from
other cell types.
Schwann Cell Enrichment and hSOD1G93A
Verification by PCR
Schwann cells and ﬁbroblast from sciatic nerve of 60-day-old
presymptomatic SOD1G93A and their wild-type controls were
obtained by ﬂuorescence activated cell sorting and submitted to
PCR for sample purity veriﬁcation. Total RNA from enriched
Schwann cells and ﬁbroblast was extracted using Trizol and
synthesized in cDNA as described above. Primers to evaluate the
presence of Schwann cells (S100) and ﬁbroblast (Thy1) used in
the PCR reactions are shown in Table 1, as well as the primer for
the internal control (Actb). The reactions were performed to 20μl
ﬁnal volume, using GoTaq Flexi DNA Polymerase (Promega),
according to the manufacturer, and 500 nM of each primer. The
protocol for PCRs consisted in 95◦C during 5min, followed by
35 cycles of 95◦C during 30 s, 60◦C during 30 s, 72◦C during
45 s, ending with 72◦C in 7min. Whole sciatic nerve sample
was used as a positive control. PCR products were submitted
to electrophoresis in 2% agarosis gel containing ethidium
bromide for 60min at 100V, and then visualized under UV
exposure.
Sciatic nerve and Schwann cells of 60-day-old
presymptomatic SOD1G93A and their wild-type controls
were submitted to PCR for veriﬁcation the presence of human
SOD1G93A (hSOD1G93A). The procedures were the same as
described above. Primers to evaluate the presence of hSOD1G93A
and Actb (internal control) used in the PCR reactions are shown
in Table 1.
Quantitative PCR
A subset of genes was chosen for veriﬁcation of
expression patterns based on their possible involvement
in ALS/neurodegeneration-related death, stress and
mitochondrion or based on their higher level of connectivity
(betweenness/degree). qPCR was performed on samples from
mouse sciatic nerves and also enriched Schwann cells as
previously described (Maximino et al., 2014). Brieﬂy, cDNA was
synthesized from 100 ng of total RNA using the Maxima First
Strand cDNA Synthesis Kit (Thermo Scientiﬁc, USA), according
FIGURE 1 | Flow cytometry cell sorting (A–D) and PCR analysis of
Schwann cell and fibroblast markers (E) from sciatic nerve of
60-day-old presymptomatic SOD1G93A and the wild-type controls.
FITC-conjugated p75NGF Receptor and PE-Cy5-conjugated Thy1 antibodies
were employed in the two-color immunolabeling of Schwann cells and
fibroblasts, respectively (A,B). Dot plots indicate the total number of events in
the sciatic nerve cell suspension, and the dots inside the box represent the
excluded doublet and dead profiles, which have been eliminated by
morphological criteria, according to previous descriptions (Herzenberg et al.,
2006) (A). After morphological criteria, dot plots of Schwann cell and fibroblast
profiles (B) were obtained using respective fluorescence filters and the blots
inside the boxes represent the specific profiles after discounting the unspecific
labeling. Positive p75NGF Receptor and Thy1 cell profiles are shown in
corresponding boxes after FITC vs. PE-Cy5 fluorescence intensity plotting (B).
Specific profiles-based on morphological criteria were further analyzed in
relation to fluorescence criteria and the specific p75NGF Receptor positive
Schwann cells profiles were identified in wild-type (median of FITC = 1142; C),
and in SOD1G93A mice (median of FITC = 1305; D). Representative bands of
PCRs for specific gene markers of Schwann cells (S100), fibroblasts (Thy1),
and actin b (Actb) were searched in Schwann cells and fibroblasts enriched
samples obtained by flow cytometry sorting of SOD1G93A mice. Mouse whole
sciatic nerve sample was used as a positive control (E).
to manufacturer’s instructions. qPCR reactions were carried out
in duplicate with 10 ng cDNA, using the DyNAmo ColorFlash
SYBR Green qPCR kit (Thermo Scientiﬁc, USA) and 400 nM
of each primer in a ﬁnal reaction volume of 20μl. Reactions
were run with the Applied Biosystems 7500 Real-Time PCR
System (Applied Biosystems). Sequence information regarding
the SYBR primers can be found in Table 1. qPCR of Foxo3
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TABLE 1 | Information of primers used to evaluate Schwann cell enrichment, demonstration of hSOD1G93A in sciatic nerve and Schwann cell samples by
PCR and to SYBR qPCR experiments in the sciatic nerve and Schwann cells isolated by means of flow cytometry sorting of 60-day-old pre-symptomatic
SOD1G93A mice.
Gene ID Primer sequences (5′–3′) Amplicon (BP)
S100 F: CCCTCATTGATGTCTTCCACC R: TCTCCATCACTTTGTCCACC 150
Thy1 F: GTCCTTACCCTAGCCAACTTC R: CCGCCACACTTGACCAG 134
hSOD1G93A F: ATCAGCCCTAATCCATCTGA R: CGCGACTAACAATCAAAGTGA 236
Ngfr F: CCTCATTCCTGTCTATTGCTCC R: TGGCTCCTTGTTTATTTTGCTTG 107
H2afx F: TTGTTCGCAGCTCTTCTACC R: GTAGTGGCCTTTCCGCAG 149
Mapk10 F: TGTTAGTGATTGACCCAGCG R: TGTGCTCCCTTTCATCCAG 141
Cdkn1a F: CAGATCCACAGCGATATCCAG R: AGAGACAACGGCACACTTTG 103
Cdkn1b F: TGGACCAAATGCCTGACTC R: GGGAACCGTCTGAAACATTTTC 144
E2f1 F: TCTCTTTGACTGTGACTTTGGG R: TCGTGCTATTCCAATGAGGC 147
Traf2 F: ACTTCACCAGAAAGCGTCAG R: GGTTTTCTCTGTAGGTCTTCCG 148
Foxo3 F: CGTTGTTGGTTTGAATGTGGG R: TGCATCACTCGTTCATCCTG 143
Mtor F: ATTCAATCCATAGCCCCGTC R: ACAGTTCCAAAGACACCAGAG 143
Erbb3 F: GGGCTATGAGACGCTACTTG R: TGCAGGACAAACTAAGGAGTG 145
Hspa1a F: TCGAGGAGGTGGATTAGAGG R: TGCAGGACAAACTAAGGAGTG 120
Prdx2 F: CCCTGAATATCCCTCTGCTTG R: TTGACTGTGATCTGGCGAAG 139
NORMALYZER
Actb F: ACCTTCTACAATGAGCTGCG R: CTGGATGGCTACGTACATGG 147
S100 (S100 calcium binding protein), Thy1 (THYmocyte differentiation antigen 1), hSOD1G93A (mutated human superoxide dismutase 1), Ngfr (Nerve growth factor receptor), H2afx
(H2A histone family, member X), Mapk10 (mitogen-activated protein kinase 10), Cdkn1a (cyclin-dependent kinase inhibitor 1A (P21)), Cdkn1b (cyclin-dependent kinase inhibitor 1B),
E2f1 (E2F transcription factor 1), Traf2 (TNF receptor-associated factor 2), Foxo3 (forkhead box O3), Mtor (mechanistic target of rapamycin-serine/threonine kinase), Erbb3 (v-erb-b2
erythroblastic leukemia viral oncogene homolog 3-avian), Hspa1a (heat shock protein 1A), Prdx2 (peroxiredoxin 2) and Actb (Actin, Beta).
was also performed on enriched ﬁbroblasts obtained from the
mouse sciatic nerves by means of ﬂow cytometry cell sorting
(Figure S1).
Thermocycling conditions for SYBR reactions included an
initial denaturation at 95◦C for 10min. Templates were ampliﬁed
for 40 cycles at 95◦C for 15 s, and for additional 40 cycles for
at 60◦C for 30 s. A dissociation curve was then generated to
ensure ampliﬁcation of a single product, and the veriﬁcation of
no primer dimer formation. A standard curve was generated for
each primer pair in order to determine the eﬃciency of the PCR
reaction over a range of template concentrations from 0.032 to 20
ng/μl, using cDNA synthesized from reference mouse RNA. The
eﬃciency for each set of primers was 100 ± 5%. Gene expression
was normalized to the expression of Actb and determined using
the Ct mathematical model (Livak and Schmittgen, 2001).
Actb was chosen as a housekeeping gene to normalize the qPCR
values because the microarray analysis showed no alteration in
expression of this gene across samples.
Statistical Analysis
The statistical method employed for the microarray analysis
is described in details in the microarray analysis section.
Furthermore, a two-tailed unpaired t-test was used to evaluate
the level of signiﬁcance of gene expression independently
between the two genotypes (SOD1G93A × wild-type) in the
qPCR analyses. Analyses were performed using the GraphPad
Prism 5 (San Diego, CA). Data were presented as Means ±
Standard Error of Mean (SEM) and signiﬁcance level was set to
p < 0.05.
Results
Qualitative Analyses of Histological Sections and
Enriched Schwann Cells of the Sciatic Nerves
No qualitative changes were found regarding morphology of
sciatic nerves of presymptomatic ALS mice compared to control
at histopathological examination (Figures 2A–J). PCR analysis
of sciatic nerve and Schwann cells enriched by ﬂow cytometry
showed the presence of hSOD1G93A in the SOD1G93A mice,
but not in the wild-type controls (Figures 2K,L). Also, the ﬂow
cytometry sorting Schwann cells of ALS mice did not show
morphological diﬀerences (cell size and cytoplasmic granules)
compared to control mice (Figures 1C,D).
Verification of Microarray Results by Quantitative
PCR
The results of qPCR veriﬁcation of 10 representative genes in
the sciatic nerve of presymptomatic SOD1G93A mice are shown
in Table 2. The up and down-regulations of the veriﬁed genes
in the sciatic nerve of 60-day-old SOD1G93A mice by means of
qPCR were coincident and supported the microarray ﬁndings of
correspondent animal ages (Table S1).
Bioinformatics Analysis
Functional Enrichment Analysis
The DAVID analysis of diﬀerentially expressed genes in the
sciatic nerve of 60-day-old SOD1G93A mice revealed 19 GO terms
of Biological Process related to cell death and apoptosis (genes
related to Death in Table 3). These GO terms of genes related
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FIGURE 2 | Histopathological analysis (A–J) and molecular evaluation
of hSOD1G93A signal (B) in the sciatic nerve and Schwann cell samples
of 60-day-old presymptomatic SOD1G93A and aged paired wild-type
mice. Immunofluorescence staining of MAP2 (A,B; red), GAP-43 (C,D; green),
S100 (E,F; green) and p75NGF (G,H; green) in the sciatic nerve of 60-day-old
presymptomatic SOD1G93A mice (B,D,F,H) and their wild-type controls
(A,C,E,G). MAP2 and GAP-43 are markers of neuronal fibers; S100 and
p75NGF are markers of Schwann cells. Cell nuclei were stained with DAPI
(blue). The insert boxes in the bottom left of images show a higher
magnification of the cell profiles. Methylene blue staining of Schwann cell
myelin sheets of sciatic nerve of 60-day-old presymptomatic SOD1G93A mice
(J) and their wild-type controls (I) are also seen. Scale bars: 10μm. Of note,
the same staining pattern was observed for both genotypes (SOD1G93A and
wild-type controls) for all cell markers and for the histological sections.
Representative bands of PCR for specific gene markers of human SOD1G93A
(hSOD1G93A) and actin b (Actb) in sciatic nerve (K) and Schwann cells
enriched samples (L) obtained by flow cytometry sorting of SOD1G93A and
wild-type control mice.
TABLE 2 | qPCR data of selected genes for verification in the sciatic nerve
of 60-day-old pre-symptomatic SOD1G93A mice.
Gene symbol Fold change p-value
Ngfr 1.88 0.0051
E2f1 1.41 0.0353
Traf2 1.37 0.0150
Erbb3 1.29 0.0390
Cdkn1a 1.26 0.0297
Foxo3 −1.96 0.0023
Hspa1a 2.06 0.0006
Prdx2 1.51 0.0359
Mapk10 1.35 0.0442
Mtor −1.23 0.0443
qPCR of differentially expressed genes in sciatic nerves of SOD1G93A mice compared
to the wild-type controls selected from microarray data (p < 0.05; see text for details).
The genes are related to death, stress and mitochondrion. The means of fold change and
p-values are shown, according unpaired two-tailed t-test. The regulation of studied genes
for verification showed the same direction as that found in the microarray experiments
(Table 3).
to Death showed 112 dysregulated genes (46 down and 66 up-
regulated genes). Furthermore, DAVID also identiﬁed two GO
terms of Biological Process related to Stress (Table 3). These
GO terms related to Stress showed 66 dysregulated genes (31
down and 35 up-regulated genes). Finally, DAVID identiﬁed
two GO terms of Cellular Components related to mitochondrial
function (Table 3). These GO terms of Mitochondrion showed
143 dysregulated genes (91 down and 52 up-regulated genes).
Table 3 shows the down regulated and up regulated genes of
Death, Stress, Mitochondrion categories with fold change equal
or higher than 1.5. The deregulated genes of these categories
with fold change smaller than that are shown in the Table S2
of the Supplementary Material. We have not expected to ﬁnd
gene regulation with high degree of fold change in this stage of
presymptomatic events, a period in which dramatic occurrences
related to inﬂammation, neurodegeneration and necrosis are not
taking place. The above-mentioned cut-oﬀ in the Table 3 is just
to facilitate the demonstration of the relatively higher deregulated
genes. All analyses of this study were performed without a cut-oﬀ.
A VEEN diagram of those dysregulated genes related to Death
and Stress and Mitochondrion showed 17 genes belonging to
both Death and Stress groups of genes, 9 genes belonging to both
Death and Mitochondrion groups of genes, 5 genes belonging
to both Stress and Mitochondrion groups of genes, and ﬁnally
3 genes belonging to the three, Death, Stress, and Mitochondrion
groups of genes (Figure 3).
The DAVID analysis of dysregulated genes related to Death,
Stress andMitochondrion shown inTable 3 are identiﬁed with 16
KEGG pathways (Table 4). Furthermore, those identiﬁed KEGG
pathways that have been previously described in the literature
as being related to ALS include RIG-I-like receptor signaling
(2 down and 3 up-regulated genes; Figure 4), tryptophan
metabolism (5 down-regulated genes; Figure 4), ErbB signaling
(1 down and 5 up-regulated genes; Figure 4) and cell cycle (2
down and 5 up-regulated genes; Figure 4). Of note, Cancer,
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FIGURE 3 | Venn diagram of differentially expressed genes related to
Death, Stress and Mitochondrion categories in sciatic nerve
(60-day-old) of SOD1G93A animals compared to wild-type controls by
means of microarray experiments. The lists of genes of the enriched
categories were obtained by means of DAVID tool based on Biological
Process and Cellular Component Ontology (EASE score set to 0.05), which
identified 112 differentially expressed genes in Death, 66 genes in Stress, and
143 genes in Mitochondrion categories. Venn diagram demonstrates genes
which are common to Death and Stress (17 genes), Death and Mitochondrion
(nine genes), and also Stress and Mitochondrion (nine genes). Three genes
(Hspa1a, Prdx2, Rrm2b) were present in the three categories (Death, Stress,
and Mitochondrion).
Small cell lung cancer, the Adipocytokine signaling pathway and
Chronic myeloid leukemia pathways are likely not related to ALS
and were not included in Table 4.
Protein Interaction Network Analysis from
Dysregulated Genes
Protein interaction network analysis using dysregulated genes
related to Death, Stress and Mitochondrion showed the hubs
(Figure 5A) TRAF2 (16 connectors), H2AFX (8 connectors)
and E2F1, FOXO3, MSH2, NGFR, TGFBR1 (7 connectors).
Furthermore, the network analysis showed ﬁve bottlenecks
(TRAF2, E2F1, CDKN1B, TWIST1, and FOXO3). The scatter
plot of the values of the hubs node degree vs. the values of
node betweenness is shown in Figure 5B. Of note, TRAF2, E2F1,
CDKN1B, FOXO3, and H2AFX occupied the highest positions
in the scatter plot (Figure 5B). Networks and scatter plots
produced from the analyses of the speciﬁc genes of Death, Stress
and Mitochondrion categories were shown in Figures S2–S5 of
Supplementary Material.
Schwann Cell and qPCR Experiments
The results of selected genes for veriﬁcation in the mouse sciatic
nerves by qPCR are shown in the Table 2. qPCR analyses of
gene expression from the enriched Schwann cells isolated from
sciatic nerves of presymptomatic 60-day-old SOD1G93A mice
identiﬁed a number of up-regulated genes including Ngfr (6.85-
fold), Cdkn1b (1.51-fold), E2f1 (1.89-fold), Traf2 (1.31-fold) and
Erbb3 (1.38-fold) related to Death (Figure 6A). The gene H2afx
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TABLE 4 | KEGG pathways obtained from gene lists related to Death, Stress and Mitochondrion from 60-day-old SOD1G93A sciatic nerve microarray
analyses.
Term Pathways Number
of genes
Categories/Genes
Death Stress Mitochondrion
mmu00280 Valine, leucine and
isoleucine degradation
12 Abat, Acaa2, Acad8, Acadsb, Acat1,
Aldh6a1, Aldh9a1, Bcat2, Bckdha,
Ehhadh, Hmgcs2, Oxct1
mmu00640 Propanoate metabolism 8 Abat, Acaca, Acacb, Acat1, Aldh6a1,
Aldh9a1, Ehhadh, Suclg2
mmu00650 Butanoate metabolism 7 Abat, Acat1, Acsm3, Aldh9a1,
Ehhadh, Hmgcs2, Oxct1
mmu00071 Fatty acid metabolism 7 Acaa2, Acadsb, Acat1, Adh1,
Aldh9a1, Cpt1a, Ehhadh
mmu04110 Cell cycle 7 Cdkn1a, Cdkn1b, E2f1, Skp2, Tgfb2 Gadd45a, Pttg1, Cdkn1a
mmu04012 ErbB signaling pathway 6 Cdkn1a, Cdkn1b, Erbb3, Pak7 Mapk10, Cdkn1a Pak7, Mapk10, Mtor
mmu00020 Citrate cycle (TCA cycle) 5 Aco1, Acly, Idh1, Idh3a, Suclg2
mmu00380 Tryptophan metabolism 5 Cat Acat1, Aldh9a1, Cat, Ehhadh, Maob
mmu00480 Glutathione metabolism 5 Gclc, Rrm2b Gclc, Rrm2b Gstz1, Idh1, Mgst1, Rrm2b
mmu00330 Arginine and proline
metabolism
5 Aldh18a1, Aldh9a1, Ass1, Glud1,
Maob
mmu04622 RIG-I-like receptor signaling
pathway
5 Traf2, Traf3 Mapk10 Mapk10, Mapk12, Nlrx1
mmu00982 Drug metabolism 5 Adh1, Gstz1, Maob, Mgst1, Ugt1a10
mmu00310 Lysine degradation 4 Acat1, Aldh9a1, Bbox1, Ehhadh
mmu00620 Pyruvate metabolism 4 Acaca, Acacb, Acat1, Aldh9a1
mmu00600 Sphingolipid metabolism 4 Sphk1, Sphk2 Asah2, Cerk
mmu00072 Synthesis and degradation
of ketone bodies
3 Acat1, Hmgcs2, Oxct1
KEGG pathways were obtained from gene lists related to Death, Stress and Mitochondrion from 60-day-old SOD1G93A sciatic nerve microarray analyses and genes included in these
pathways and categories are shown in the table. EASE score was set to 0.05.
(1.42-fold) of the Stress group was up-regulated. The genes
Cdkn1a (1.95-fold) and Foxo3 (-1.67-fold) from the Death and
Stress groups were up- and down regulated, respectively. The
genes Hspa1a (4.48-fold) and Prdx2 (1.48-fold) of the Death,
Stress and Mitochondrion groups were up-regulated. Mapk10
(1.42-fold) of the Stress and Mitochondrion groups was up-
regulated and Mtor (−1.86-fold), related to mitochondrion, was
down regulated (Figure 6B). Interestingly, the expression of
Foxo3 was not altered in the enriched ﬁbroblasts of the mouse
sciatic nerve (Figure S1).
Discussion
Triggering Mechanisms of Motor Neuron Death in
ALS
Several mechanisms have been proposed as triggers for both
autonomous and non-autonomous events related to motor
neuron death in ALS. Events of oxidative stress, neuroimmune
reactions, protein aggregation, glutamate excitotoxicity,
mitochondrial dysfunction and impaired axonal transport in
ALS are currently under investigation (Bruijn et al., 2004; Boillée
et al., 2006a; de Vos et al., 2007; Jaiswal and Keller, 2009; Redler
and Dokholyan, 2012).
The initial triggering and the secondary reactive events
associated with motor neurons and their neighboring glial
cells are unknown (Tapia, 2014). For instance, early ﬁndings
related to morpho/physiological changes have been described
in presymptomatic phases of the ALS mouse model (Boillée
et al., 2006a; Ferraiuolo et al., 2007; Alves et al., 2011;
de Oliveira et al., 2013, 2014; Maximino et al., 2014). Of
note, fragmentation of the Golgi apparatus (Mourelatos et al.,
1996), vacuolization of mitochondria (Bendotti et al., 2001),
deﬁcits in axonal transport (Ikenaka et al., 2012), endoplasmic
reticulum stress (Tadic et al., 2014), the activation of glial cells
(microglia and astrocytes) (Nagai et al., 2007; Graber et al.,
2010) and electrophysiological changes (Quinlan, 2011) have
all been described within motor neurons and neighboring cells
at early postnatal ages. Technological advances have facilitated
the discovery of molecular events underlying both autonomous
(Wada et al., 2012) and non-autonomous (Ferraiuolo, 2014)
mechanisms possibly related to early presymptomatic neuronal
toxicity in ALS (Arbour et al., 2015; Saba et al., 2015).
Evidence indicates the existence of very early events, possibly
anticipating the motor neuron death, that take place peripherally,
i.e., in the motor nerve, motor nerve terminals, neuromuscular
junction and muscle (Rocha et al., 2013; de Oliveira et al., 2014;
Moloney et al., 2014). In fact, very early electrophysiological
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FIGURE 4 | KEGG pathways showing the number of transcripts up
(right side bars with positive values) and down-regulated (left side bars
with negative values). The figure is representative of the KEGG pathways
(EASE score was set to 0.05) obtained from the GO terms list containing
genes related to death, stress and mitochondrion that have been already
mentioned in the ALS literature. The categories were composed by seven
genes (Cell cycle), six genes (ErbB signaling pathway), five genes (Tryptophan
metabolism and RIG-I-like receptor signaling pathway).
events in the motor nerve precede cell body disappearance in
the spinal cord as well as the onset of clinical symptoms in ALS
(Alves et al., 2011). Absence of neuronal death or morphological
alterations in the motor neuron cell bodies has been described in
the 60-days-old presymptomatic SOD1 mice (Fischer et al., 2004;
Gould et al., 2006; Casas et al., 2013).
Remarkably, early morphological, biochemical and molecular
changes in peripheral non-neuronal cells, i.e., Schwann cells
and skeletal muscles, are emerging as dying-back mechanisms
of motor neuron degeneration in ALS (de Winter et al., 2006;
Dupuis and Loeﬄer, 2009; Dupuis et al., 2009; Keller et al., 2009;
Narai et al., 2009; Chen et al., 2010; Dadon-Nachum et al., 2011;
Venkova et al., 2014). In fact, the involvement of Schwann cells,
which maintain close morphological/physiological relationships
with motor axons, has gained more attention in ALS (de Winter
et al., 2006; Keller et al., 2009; Chen et al., 2010; Maximino et al.,
2014; Venkova et al., 2014). Our work has contributed to a more
detailed understanding of the mechanisms involved in the dying-
back events associated with motor nerves in ALS by performing a
large-scale gene proﬁling analysis utilizing a microarray analyses
in the sciatic nerve of presymptomatic ALS mice.
A deﬁcit in the paracrine trophic interactions between
Schwann cells and motor neurons in presymptomatic ALS is a
logical choice for further study since Schwann cells oﬀer the main
source of trophic stimuli for the maintenance of mature motor
neurons (Bhatheja and Field, 2006) and for the regeneration
of their ﬁbers after injury (Gupta et al., 2005). In support of
this hypothesis, mSOD1 gene expression in distal Schwann cells
has been suggested to interfere with the trophic maintenance
of motor axon projections (Inoue et al., 2003). Also, reduction
of Schwann cell-derived insulin growth factor-1 and cilliary
neurotrophic factor in sciatic nerves of both ALS mice and
FIGURE 5 | Protein interaction network developed from differentially
expressed genes related to Death, Stress and Mitochondrion of sciatic
nerves from SOD1G93A mice (A). Scatter plot of the correlation between
highest values of node degree (hubs) and node betweenness (bottlenecks) is
shown in (B), as described in the text. Up and down-regulated genes are
represented respectively as red and green diamonds. Nodes with the highest
values for node degree (number of connections) and node betweenness
(number of shortest paths) are represented with a yellow border. Of note from
this analysis, the genes E2f1, Foxo3, Gli3, Ngfr, Cdkn1a or their related
products were already described in the context of ALS.
patients have been correlated to disease worsening (Lee et al.,
1996; Lobsiger et al., 2009).
In addition to a deﬁcit in paracrine trophic factor
maintenance, the presence of toxic factors from Schwann
cells aﬀecting motor neurons at early presymptomatic stages
in ALS is an additional matter for investigation. Indeed, our
DAVID analyses of dysregulated gene expression in sciatic
nerves of presymptomatic SOD1G93A mouse model highlighted
the GO categories death, stress and mitochondrion, which may
be related to the above mentioned possibilities. Of note, the
ﬁndings of a high number of dysregulated genes related to
death, with many also included in the stress and mitochondrial
function categories, indicated a complex regulation of these
events before motor neuron death, as described for other
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FIGURE 6 | Relative fold change values of selected dysregulated genes
related to death, stress and mitochondrion by qPCR in enriched sciatic
nerve-derived Schwann cell samples of 60-day-old SOD1G93A (TG)
mice compared to the age matched wild-type (WT) mice. Schwann cells
were enriched by means of flow cytometry cell sorting technique from the
sciatic nerves of the mice. Significant increases in expression are seen in
genes related to Death (Ngfr, Cdkn1b, E2f1, Traf2, and Erbb3; A).
Up-regulated H2afx is related to Stress category (B). Down-regulated Cdkn1a
and Foxo3 are related to Death and Stress categories respectively (B).
Up-regulated Hspa1 and Prdx belonged to Death, Stress and Mitochondrion
categories (B). Up-regulated Mapk10 (Stress and Mitochondrion categories)
and down-regulated Mtor (Mitochondrion) were also shown down-regulated
(B). A pool of the non-ALS group was used as reference samples with a
reference value of 1, see text for details. Means ± SEM; n = 6 for each group;
* and **p-values indicates the <0.05 and <0.01 levels of significance,
respectively, according to unpaired two-tailed t-test.
neurodegenerative disorders (Friedman et al., 1996; Gatzinsky
et al., 2003; Pun et al., 2006; Campana, 2007; Lobsiger et al.,
2009; Nobbio et al., 2009a,b). Conversely, negative and positive
gene regulation related to death and anti-apoptosis mechanisms
were also identiﬁed in several categories of dysregulated genes,
indicating a concomitant regulation of cell toxicity/maintenance
before neurodegeneration during the presymptomatic stages in
ALS. It should be emphasized that the present description of
gene proﬁling in the sciatic nerve in the presymptomatic ALS
mouse model may represent predominantly the regulation of
Schwann cells transcripts. In fact, as discussed below, the qPCR
veriﬁcation of selected genes in the mouse sciatic nerve tissue
has conﬁrmed the microarray results. qPCR results of selected
genes in the enriched Schwann cells were also coincident to
microarray. Conversely, the regulation of Foxo3 in the enriched
ﬁbroblasts of the sciatic nerve was in the opposite direction.
Mitochondrial/Oxidative Stress Mechanisms
Related to Presymptomatic Motor Neuron
Impairment
Motor neurons are susceptible to reactive oxygen species and
oxidative stress due to their high metabolic rates and decreased
ability to buﬀer calcium (Shaw and Eggett, 2000). Long axons
and increased functional activity also confer a high susceptibility
to mitochondrial impairments in motor neurons (Barber et al.,
2006; Pizzuti and Petrucci, 2011; Cozzolino et al., 2013).
Altered morphology of motor neuron mitochondria has been
described in an ALS mouse model (Parone et al., 2013) as well
as in humans (Hirano et al., 1984b) at both histological (Hirano
et al., 1984a,b) and ultrastructural (Sasaki and Iwata, 1996) levels.
Of note, swollen and vacuolated mitochondria were found in
motor neurons, glial cells and muscles in ALS (Aﬁﬁ et al., 1966;
Atsumi, 1981; Siklós et al., 1996; Sasaki et al., 2007; Cassina et al.,
2008).
Furthermore, oxidative stress has been described in several
regions of the brain (Ferrante et al., 1997; Bogdanov et al.,
1998, 2000), in the spinal cord (Shaw et al., 1995; Andrus et al.,
1998; Liu et al., 1998, 2004; Shibata et al., 2002) and in the
skeletal muscle (Mahoney et al., 2006) of both ALS mice and
humans. Altered levels of reactive oxygen species within the
spinal cord mitochondria of ALS mice (Jung et al., 2002) and
patients (Bogdanov et al., 2000) support a possible impairment of
the electron transport chain and energy defects in this disorder.
Indeed, mitochondrion-induced damage to motor neurons has
previously been mentioned as an early ALS signal (Wong et al.,
1995; Mattiazzi et al., 2002; Kirkinezos et al., 2005; Cassina
et al., 2008; Loizzo et al., 2010). Furthermore, peroxynitrite
and superoxide overload in reactive astrocytes and microglia
in in vitro models of ALS lead to protein impairment-induced
motor neuron damage (Hensley et al., 2006; Dadon-Nachum
et al., 2011). These studies all underline the critical involvement
of mitochondrial dysfunction in early autonomous and non-
autonomous pathogenesis of ALS.
Interestingly, increases in inducible nitric oxide synthase
and peroxynitrite in Schwann cells and motor axons of
paranodal regions in presymptomatic ALS mice were associated
with local mitochondrial reactive oxygen species formation
(Chen et al., 2010). Furthermore, Schwann cell-induced trophic
support failure and Schwann cell-induced mitochondrial toxicity
to motor neurons have both been correlated with high
levels of mSOD1 in those peripheral glia of presymptomatic
SOD1G93A ALS mice (Gould et al., 2006). Thus, Schwann cell
mitochondrion/oxidative stress mechanisms seem to play a key
role during the early stages of ALS.
KEGG Pathways Related to Death, Stress and
Mitochondrion in ALS
Our DAVID analyses identiﬁed genes associated with death,
stress and mitochondrial function from the complete list
of dysregulated genes of the sciatic nerve from 60-day-old
presymptomatic ALS mice before the onset of neurological
impairment.
Dysregulated genes of death signaling (Olsen et al., 2001;
Hensley et al., 2002; Yoshihara et al., 2002; Dangond et al., 2004;
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Ferraiuolo et al., 2007; Guipponi et al., 2010) and also those
of stress and mitochondrion-related signaling (Dangond et al.,
2004; D’arrigo et al., 2010; Guipponi et al., 2010; Bernardini et al.,
2013) have been described in ALS models (spinal cord and motor
neurons) and in patients (e.g., from post mortem spinal cord
and skeletal muscle biopsy) by means of microarray technology.
Thus, our work supplements those cited by providing a large-
scale proﬁle of genes related to death, stress and mitochondrial
function in the peripheral motor nerves of presymptomatic ALS
mice.
KEGG pathways from the dysregulated genes associated
with death, stress and mitochondrial function of sciatic nerves
of presymptomatic ALS mice identiﬁed valine, leucine and
isoleucine degradation and propionate metabolism as pathways
with the highest number of dysregulated genes. Of note,
impairments in valine, leucine and isoleucine metabolism
(Ilzecka et al., 2003) but not in propionate metabolism, have
been described in the context of ALS. Furthermore, fatty
acid metabolism, citrate cycle, gluthatione metabolism, arginine
and proline metabolism, pyruvate metabolism, sphingolipid
metabolism, synthesis and degradation of ketone bodies, and
beta-alanine metabolism pathways have been correlated with the
onset of ALS (Ariga et al., 1998; Schulz et al., 2000; Cutler et al.,
2002; Zhao et al., 2006; Nunn and Ponnusamy, 2009; Panov et al.,
2011; Dormann et al., 2012; Zhang and Chook, 2012; de Munck
et al., 2013; Yip et al., 2013; Allen et al., 2014). Additionally,
dysregulated genes related to RIG-I-like receptor signaling (Day
et al., 2005; Katsuno et al., 2011; Zhu et al., 2014), tryptophan
metabolism (Sandyk, 2006), ErbB signaling (Gorlewicz et al.,
2009), and cell cycle (Manzano et al., 2013) have been reported
in ALS (Gorlewicz et al., 2009; Manzano et al., 2013).
Interestingly, the majority of dysregulated genes of the KEGG
pathways RIG-I-like receptor signaling, ErbB signaling and cell
cycle were found to be up-regulated. Conversely, all genes
of tryptophan metabolism were down regulated in the sciatic
nerve of presymptomatic ALS mice. The understanding on how
such a complex regulation of important singling pathways may
represent early triggering or reactive responses in the dying-
back mechanisms in ALS is a matter for further analyses.
RIG-I-like receptor genes are regulated in ALS, however, the
exact mechanisms by which innate immune activation may
drive neuronal death in neurodegenerative disorders are far
from elucidated. In particular, the role of RIG-I-like receptor
gene products in those mechanisms underlying glial cell
activation, misfolded proteins/aberrantly localized nucleic acids
andmitochondrion signaling-induced autophagy remain unclear
(Kawai and Akira, 2008; Tal and Iwasaki, 2009; Heneka et al.,
2014; Ying et al., 2015). Furthermore, the involvement of ErbB
signaling in ALS was raised with the description of disrupted
neuregulin-ErbB4 pathway signaling in presynaptic synapses of
less resistant spinal cord motor neurons (Takahashi et al., 2013),
but not in the resistant oculomotor neurons in human ALS
(Gallart-Palau et al., 2014). Furthermore, ErbB signaling may
inﬂuence non-autonomous microglial ALS mechanisms (Falls,
2003; Esper et al., 2006; Song et al., 2012) as well as Schwann cell-
induced motor axon terminal changes in ALS (Gorlewicz et al.,
2009).
The large-scale down-regulation of genes associated with the
tryptophan metabolism pathway may be related to serotonin’s
ability to modulate glutamate motor neuron transmission
(Palchaudhuri and Flügge, 2005), and thus excitotoxicity in ALS.
Indeed, evidence of serotonin deregulation has been obtained
from studies on ALS patients (Sandyk, 2006).
As discussed below, cell cycle gene regulation in the sciatic
nerve in presymptomatic phases of ALS might disrupt the
normal interactions between reactive Schwann cells and motor
axons. In fact, cell cycle impairments have been described
in neurodegenerative diseases (Van Leeuwen and Hoozemans,
2015; Wojsiat et al., 2015) and the interaction between mSOD1
and cyclin regulators seems to contribute to autonomous and
non-autonomous mechanisms in ALS (Nguyen et al., 2003;
Ranganathan and Bowser, 2003; Cova et al., 2010).
Schwann Cell Genes Related to Death, Stress
and Mitochondrial Function in the Sciatic Nerve
of Presymptomatic ALS Mouse Model
Our study demonstrated the existence of highly interconnected
genes from the lists of dysregulated genes involved in death and
stress signaling as well as mitochondrial function in the sciatic
nerve of presymptomatic ALSmice. The regulation of these genes
was further evaluated in the enriched Schwann cells from the ALS
mice using qPCR.
Traf2, E2f1, and Cdkn1b from the list of genes of GO
biological process related to death were identiﬁed as nodes with
highest values for node degree (number of connections) and
node betweenness (number of shortest paths) in the Protein
interaction network analysis.
Mutant SOD1 led to TNF-α pathway activation in the absence
of inﬂammation in ALS (Carter et al., 2009), an event that may
also occur in Schwann cells (Au and Yeh, 2007) based on the
results of Traf2 up-regulation in ALS Schwann cells described in
our work.
TNFα is a potent regulator of Schwann cell division
(Chandross et al., 1996) and activation (Bonetti et al., 2000).
Moreover, despite a lack of histopathological descriptions of
peripheral nerves from ALS subjects and animal models (Fischer
et al., 2004; Kano et al., 2012), there are no reports describing
local Schwann cell division or death. However, up-regulation
of markers of glial activation indicated an early process of
Schwann cell reaction in ALS peripheral nerves (Keller et al.,
2009; Malaspina et al., 2010). Cell division is a common feature
of activated central glia (Pekny and Nilsson, 2005; Dheen et al.,
2007). Therefore, it might be possible that the absence of cell
division would disrupt normal functions of activated Schwann
cells in presymptomatic stages of ALS.
It is likely that the up-regulation Cdkn1b and E2f-1
may lead to intracellular mobilization of cell-cycle proteins
and transcriptional regulators in ALS glia (Weinberg, 1995;
Ranganathan and Bowser, 2003) and also in ALS activated
Schwann cells. These events may interfere with the balance
between death/survival signaling pathways in TNFα-activated
Schwann cells (Tang et al., 2013), possibly altering the normal
functions of activated Schwann cells and leading to a failure
of trophic surveillance and/or to toxicity signaling in ALS
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(Ranganathan and Bowser, 2003; Cova et al., 2010). Therefore,
the absence of hyperplasia may impair substantially the paracrine
trophic mechanisms of TNFα-activated Schwann cells with
motor neurons in ALS.
Other nodes with high values for connections and
betweenness described in the Protein interaction network
analysis support a non-autonomous mechanism of activated
Schwann cells in ALS. The nodes Ngfr, Erbb3, and H2afx of
dysregulated genes from the death list further indicated the
presence of impaired paracrine trophic functions of Schwann
cells in ALS. The up-regulation of Ngfr and Erbb3, which
encode the high-aﬃnity neurotrophin receptor TRKA and the
neuregulin-associated tyrosine kinase receptor, respectively,
could be involved in Schwann cell paracrine functions (Wang
et al., 1996; Lyons et al., 2005; Adilakshmi et al., 2011) as well
as in early, complex mechanisms of axonal retraction and
neuromuscular junction alterations in ALS prior to motor
neuron degeneration (Kerkhoﬀ et al., 1991; Gorlewicz et al.,
2009). Furthermore, the up-regulation ofH2afx in Schwann cells
might correlate with the described Schwann cell participation in
the pathogenesis of ALS since H2AFX-induced DNA damage in
reactive astrocytes has been associated with impaired paracrine
glial functions in other neurodegenerative disorder (Simpson
et al., 2010).
Foxo3 and Cdkn1a are present in the death and stress
lists of genes and were also found to be dysregulated in the
enriched Schwann cells from the sciatic nerve of 60-day-old
presymptomatic ALS mice. Indeed, the encoded products of
these genes have been investigated in ALS skeletal muscles
but not in the ALS motor nerve (Léger et al., 2006; Gonzalez
de Aguilar et al., 2008; Manzano et al., 2013). Foxo3 showed
high levels of betweenness and degree and FOXO3 has been
studied as a catabolic target in ALS skeletal muscles (Léger
et al., 2006). Conversely, Cdkn1a dysregulation was described
in muscles of ALS mice (Gonzalez de Aguilar et al., 2008)
and CDKN1A, a cyclin-dependent kinase inhibitor, interferes
with satellite cell-induced myoplasticity in ALS skeletal muscles
(Manzano et al., 2013). The above ﬁndings provide support
for the involvement of Foxo3 and Cdkn1a in the dying-back
Schwann cell mechanisms in ALS, a matter that should be further
investigated.
Hspa1a, Prdx2, and Rrm2b were present in three GO lists,
the death, stress, and mitochondrial function categories. Hspa1a
and Prdx2 were also found to be dysregulated in the enriched
Schwann cells from the sciatic nerves of presymptomatic
ALS mice. Those three genes and their encoded products
have not been described in the context of ALS. Moreover,
up-regulation of Hspa1a and Prdx2 were found in other
neurodegenerative disorders and their encoded products have
been studied in the context of therapeutic strategies (Muchowski
and Wacker, 2005; Ali et al., 2010; Gestwicki and Garza,
2012). Furthermore, RRM2B-related mitochondrial diseases are
frequently inherited and associated with neurological symptoms
(Horga et al., 2014). Conversely, non-inherited mitochondrial
dysfunctions have been suggested as possible mechanisms
underlying the pathogenesis of ALS (discussed above). Thus,
mitochondria/oxidative stress impairing Schwann cell paracrine
regulation in the presymptomatic phases of ALS is a matter for
further investigation.
Mtor, identiﬁed in the mitochondrion list of dysregulated
genes, was down-regulated in the enriched Schwann cells from
presymptomatic SOD1 mice, a change which is in line with
descriptions of MTOR reduction in spinal cords of ALS rodents
(Morimoto et al., 2007). MTOR reduction induced by PI3-K and
Akt/PKB signaling (Nagano et al., 2002) worsened ALS pathology
in ALS transgenic mice (Zhang et al., 2011). Because MTOR
activation leads to neuroprotection in ALS (Saxena et al., 2013), it
is a matter of further investigation whether modulation ofMTOR
signaling in Schwann cells could counteract the degenerative
processes associated with this disease.
Finally, Mapk10 of mitochondrion and stress categories was
found to be up-regulated in the enriched Schwann cells from
sciatic nerves of presymptomatic ALS mice. A MAPK10/JNK3
truncation mutation has previously only been associated with
cognitive disorders (Kunde et al., 2013). Furthermore, Mapk10
itself has not been investigated as a factor in the pathogenesis
of ALS, despite the general consensus that deregulated MAPK
signaling contributes to ALS (Kim and Choi, 2010; Xia et al.,
2015). Nevertheless, the involvement of p38MAPK and TNFα
receptors in the non-autonomous microglial toxicity in ALS
(Veglianese et al., 2006) raised the possibility of a similar
mechanism in ALS Schwann cells, an issue that should be
explored further.
In conclusion, our large-scale gene proﬁling reveled the
presence of death, stress (with emphasis on oxidative stress),
and mitochondrial function pathway signaling taking place in
the sciatic nerve of presymptomatic ALS mice. The regulation
of highly interconnected genes in ALS Schwann cells indicated
the involvement of these pathways in the non-autonomous
mechanisms of that peripheral glial cell type in the early stages
of the disorder.
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